>>Signaling Pathways>> Immunology/Inflammation>> TLR>>CU-CPT-9b (TLR8-specific antagonist 1)

CU-CPT-9b (TLR8-specific antagonist 1)

Catalog No.GC31729

CU-CPT-9b(TLR8 특이적 길항제 1)는 0.7 nM의 IC50을 갖는 특이적 TLR8 길항제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

CU-CPT-9b (TLR8-specific antagonist 1) Chemical Structure

Cas No.: 2162962-69-6

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$151.00
재고 있음
5mg
US$138.00
재고 있음
10mg
US$220.00
재고 있음
50mg
US$689.00
재고 있음
100mg
US$1,103.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CU-CPT-9b is a specific TLR8 antagonist, with an IC50 of 0.7 nM.

CU-CPT-9b is a specific TLR8 antagonist, with an IC50 of 0.7±0.2 nM. ITC experiments have confirmed the strong binding of CU-CPT-9b with a Kd of 21 nM. It is shown that CU-CPT-9b binds to the inactive TLR8 dimer in a similar way to CU-CPT8m. CU-CPT9b utilizes hydrogen bonds with G351 and V520*, which are conserved among TLR8/antagonist structures. Additionally, CU-CPT-9b forms water-mediated contacts with S516* and Q519*, which are not observed in TLR8/CU-CPT8m structure, suggesting that the enhanced potency of CU-CPT-9b derives from the new interactions with these polar residues. The orientation of Y567* also changes to facilitate van der Waals interactions with CU-CPT-9b as compared to TLR8/CU-CPT8m[1].

[1]. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018 Jan;14(1):58-64.

리뷰

Review for CU-CPT-9b (TLR8-specific antagonist 1)

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CU-CPT-9b (TLR8-specific antagonist 1)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.